- Welcome to the Institute's new Internet
- Stem cell technique offers new potential to treat blindness
- 20% of adult obesity might be caused by infant nutrition
- Study to reduce birth defects
- Beta thalassaemia gene therapy success
- Genetic link with human male infertility identified
- New research into Congenital Toxoplasmosis endorses UK health guidance for pregnant women
- ICH Poster Competition and Open Day
- Is 'breast only' for first six months best?
- Six months of exclusive breast feeding: how good is the evidence?
- Major new programme to tackle childhood obesity launched
- Study shows that early detection of Severe Combined Immunodeficiency would save lives
- £28 Million boost to understand child health
- The impact of sex selection and abortion in China, India and South Korea
- Regenerative medicine success for muscles
- New study examines early-onset eating disorders in under-13s
- International 50-year mortality trends in children and young people reveal an inadequate response to the health problems and causes of death in adolescents, particularly young men
- Apples, oranges and jam – the tasty way to keep kidney disease at bay
- Scientists prove heart has built-in repair mechanism: Exciting breakthrough towards mending broken hearts
- Fight for Sight awards £1 million for retinal disease research
- New Policy Research Unit in the Health of Children, Young People and Families
- UCLB and NCYPE announce a commercialisation agreement with Special Products Limited for Epistatus®
- Molecular scalpel hope for Duchenne muscular dystrophy
- Eating disorders linked to fertility problems and negative feelings towards pregnancy
- Science: From Cradle to Grave
- £36 million boost for children's health research
- Gene therapy success for children born without functioning immune system
- ICH Open Day 2011
- Under 16s make up less than one per cent of NHS patient surveys
- Mitochondria genes and cardiomyopathy
- Child Health Research PhD Studentships 2012-13
- Tate Liverpool exhibition inspires pioneering science games
- No consistent decrease in child maltreatment despite years of policy initiatives designed to achieve it
- New approach on bone marrow transplant infections
- Genetic testing for antibiotic related deafness
- Great Ormond Street Hospital Children’s Charity announces plans to build a Centre for Children’s Rare Disease Research
- Gene therapy shows clinical effect in third immune disease
- Clean delivery kits linked to substantial reduction in neonatal deaths in South Asia, study shows
- Genetic variant inherited from the mother significantly increases birth weight
- Not enough is known about prescription drug use in pregnancy, say experts
- Improving access to education and employment and reducing the risk of transport-related injury are among the best ways to improve adolescent health
- Research reveals association between red hair gene and rare birthmarks
- Five new UCL fellows of Academy of Medical Sciences
- Surgery boost for children with drug-resistant epilepsy.
- Professor of economics and deputy director appointed to the new UK Birth Cohort Study
- First example of a heritable abnormality affecting semantic cognition found
- New Director of the UCL Institute of Child Health
- New approach to recording suspected child abuse in patient records
- Amniotic fluid yields alternatives to embryonic stem cells
- ICH OPEN DAY AND POSTER COMPETITION
- Europe’s first research centre to battle birth defects
- New cause of thyroid hormone deficiency discovered
- £10 million boost for Centre for Children’s Rare Disease Research
- EU awards grant to develop new drug for Duchenne muscular dystrophy
- New research centre for teenagers with arthritis
- Major study shows steep decline in figure for diagnosed epilepsy
- Obesity leads to vitamin D deficiency
Gene therapy success for children born without functioning immune system
25 August 2011
Papers published today in Science Translational Medicine report success in two established gene therapy programmes to cure children born unable to fight infection.
The programmes, which looked at X-SCID and ADA-SCID, were led by Professors Adrian Thrasher and Bobby Gaspar of the UCL Institute of Child Health (ICH).
14 out of 16 patients across the two programmes were successfully treated.
The work was funded by Great Ormond Street Hospital Children’s Charity, Wellcome Trust, The Primary Immunodeficiency Association and the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital.
In the treatment of X-SCID, commonly known as ‘boy in the bubble’ syndrome, ten out of ten patients show clear clinical benefits and have no social restrictions1. One child regrettably developed leukaemia and is currently in remission2. As a result, safer vectors were developed and are now being used.
X-SCID is caused by mutations in the IL2RG gene, which governs the behaviour of a protein involved in the development of a number of immune system cells.
In a programme looking at ADA-SCID, four out of six children treated show clear clinical benefit and have no social restrictions. ADA-SCID results from the lack of an enzyme that helps cells to get rid of toxic byproducts.
Children involved in both programmes continue on some medication, but five of the ten X-SCID and three of the four ADA-SCID patients no longer take immunogloblins.
Professor Thrasher, consultant in paediatric immunology and X-SCID programme lead said: “These are excellent results for our gene therapy programmes and the first time we have been in a position to say we have found a cure for patients with these conditions. It demonstrates that gene therapy for immune diseases is now mainstream, and we hope this approach will benefit many more of our patients in the future.”
Professor Gaspar, consultant in paediatric immunology and ADA-SCID programme lead said: “We are delighted by the results of both of these programmes.
“The success of the ADA-SCID programme has also saved the NHS millions of pounds, as these children are able to stop receiving regular costly enzyme replacement injections.
“Worldwide, 30 children have received gene therapy for ADA-SCID, none of whom have died and 70 per cent of whom have seen a clear clinical benefit.
“We are now leading trials for two other immune disorders with colleagues from across the globe, and hope that gene therapy will now be seen as a standard alternative to conventional treatments such as bone marrow transplant.
“We also hope to be able to extend this approach to other conditions, such as lysomal storage diseases, where a metabolic fault means chemicals build up in cells and cause various problems throughout the body.
Gaynor Harnden’s son Guy, 6, was enrolled on the X-SCID programme. She said: “Guy is now doing brilliantly, he can do all of the things his friends can and more. He is able to play football and ride a pony.
“He wouldn’t be here if it wasn’t for the option of gene therapy treatment. We are incredibly grateful to the whole team at Great Ormond Street Hospital, but especially Adrian Thrasher and Bobby Gaspar who pioneered this work. To other parents who find themselves in our situation we would say ‘go for it’”.
Great Ormond Street Hospital runs more gene therapy trials for immune deficiency in children than any other centre in the world. The papers come over a decade after Rhys Evans became the first boy to be successfully treated for X-SCID by gene therapy at the hospital. The first patient to undergo ADA-SCID treatment is now almost eight years post gene therapy.
Page last modified on 25 aug 11 09:34